TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Renal Impairment on the Pharmacokinetics of NN9535

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)~* Subjects meeting the pre-defined GFR (glomerular filtration rate) criteria (estimated by the Cockcroft \& Gault formula) for any of the renal function groups~* Body Mass Index (BMI) equal to or less than 40kg/m2~Exclusion Criteria:~* Known or suspected allergy to trial product(s) or related products~* Renal transplanted patients~* Certain cardiac problems (heart failure, unstable angina, MI (myocardial infarction) within the last 3 months)~* Known current hepatic dysfunction or severe hepatic disease during the last 12 months~* Female of childbearing potential/breast feeding~* History of alcoholism or drug abuse~* Blood donation during the last 8 weeks prior to the study~* Past or current history of pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female between 16- to 26-years-old~* Has never had Pap testing or has only had normal Pap (Papanicolaou) test results~* For the immune memory substudy in the extension (Cohort 1): was randomized to V503 in the base study and was in the per-protocol immunogenicity population for ≥1 HPV type~* For the 3-dose V503 vaccination substudy in the extension (Cohort 2): was randomized to GARDASIL in the base study and received ≥1 dose of GARDASIL~Exclusion Criteria:~* History of an abnormal cervical biopsy result~* History of a positive test for HPV~* History of external genital/vaginal warts~* Currently a user of any illegal drugs or an alcohol abuser~* History of severe allergic reaction that required medical attention~* Are pregnant~* Received marketed HPV vaccine or participated in an HPV trial~* Currently enrolled in a clinical trial~* Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent.)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose V503 (Type: EXPERIMENTAL): V503 (9-Valent Human Papillomavirus \[HPV\] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
- Mid-dose V503 (Type: EXPERIMENTAL): V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
- High-dose V503 (Type: EXPERIMENTAL): V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
- Gardasil (Type: ACTIVE_COMPARATOR): Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eosinophilic fasciitis as defined by clinical judgement of an expert,~* Histologically confirmed with a skin-fascia-muscle biopsy, and in additon:~  * Either the presence of a modified skin score according to Zachariae of 8 or higher (0-18), regarded as a generalised eosinophilic fasciitis or the presence of severe contractures due to eosinophilic fasciitis lesions.~Exclusion Criteria:~* Age \< 18 yrs~* Contraindications to MTX: AST/ALT level \> 2 times upper limit of normal, WBC count \< 3.5 x 109/l or platelet count \< 150 x 109/l, serum creatinine \> 130 micromol/l or clearance \< 50 ml/min, confirmed by two repeated tests within one month.~* Chronic liver disease, insulin dependant diabetes mellitus, alcohol abuse~* Restrictive pulmonary disease (total lung capacity or vital capacity \< 40% of predicted) or interstitial lung disease (KCO \< 60% of predicted)~* Pregnancy or child bearing potential without adequate contraception~* The presence of any serious co-morbidity or malignancy~* Use of other anti-folate drugs than MTX

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Positive ANA result at visit 1~* Current diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology revised criteria such that at least 4 of the 11 criteria are met~* Active moderate or severe SLE disease activity as demonstrated by British Isles Lupus Assessment Group (BILAG) A level disease activity in at least one body/organ system or BILAG B level disease activity in at least two body/organ systems if no BILAG A level disease is present~* If on antimalarials, dose regimen must be stable for 4 weeks prior to study entry.~Exclusion Criteria:~* Patients receiving any live vaccination within 2 weeks prior to visit 1 or during the course of the study~* Active severe SLE disease activity which involves the central nervous system (CNS) (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures~* Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher World Health Organization (WHO) nephritis) or serum creatinine \>2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria \>3.5gm/day~* Patients with a history of anti-phospholipid antibody syndrome AND use of oral anticoagulants or anti-platelet treatment~* Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
- EMAB 600mg (Type: EXPERIMENTAL): 600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
- EMAB 100mg (Type: EXPERIMENTAL): 100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
- EMAB 400mg (Type: EXPERIMENTAL): 400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
- EMAB 1200mg (Type: EXPERIMENTAL): 1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
- EMAB 1800mg (Type: EXPERIMENTAL): 1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Guanfacine on Delirium in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Patients admitted to the UAB hospital Surgical Intensive Care Unit (SICU)~* 18 years of age or older~* Expected total ICU length of stay of 72 hours or more per treating physician~* Diagnosed with delirium based on CAM-ICU assessment (see attached CAM-ICU assessment form)~Exclusion Criteria~* Patients younger than 18 years old~* Expected discharge from ICU within 72 hours of admission~* Expected or inevitable death with 48 hours of enrollment~* Pregnancy or breast feeding~* Non-English speaking~* Patients unable to be assessed by CAM-ICU due to neurologic illness~* Altered consciousness unable to participate in CAM-ICU assessment~* Patients with previous diagnosis of chronic, acute, subacute neurologic disease, or neurodegenerative disease~* Mental illness and/or psychosis~* Acute alcohol withdrawal~* No enteral route available for administration~* Treating physician refusal of enrollment based on severe hypotension (defined as requiring a vasopressor for longer than 24 hours) or bradycardia (Hr\<50 bpm) at the time of screening~* Hepatic encephalopathy~* Blind or Hearing impaired~* Taking Guanfacine, for any reason~* On CYP3A inhibitor such as azole antifungals or clarithromycin~* On CYP3A inducers such as phenytoin or rifampin~* Severe xerostomia~* Enrolled in another interventional research trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
- Guanfacine (Type: EXPERIMENTAL): Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block for Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 yrs~* American Society of Anesthesiologists physical statusⅠ-Ⅲ~* Undergo hepatectomy with J-shape subcostal incision~* Informed consent~Exclusion Criteria:~* A known allergy to the drugs being used~* Coagulopathy, on anticoagulants~* Analgesics intake, history of substance abuse~* Participating in the investigation of another experimental agent~* Unable to cooperate, eg. inability to properly describe postoperative pain to investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PTPVB-ropivacaine (Type: EXPERIMENTAL): Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
- PTPVB-saline (Type: PLACEBO_COMPARATOR): Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>18 years old)~* Early-stage breast cancer patients who will receive adjuvant paclitaxel~* Performance status according to Eastern Cooperative oncology group (ECOG) \< 2.~* Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine\<1.5 mg/dl).~Exclusion Criteria:~* Clinical neuropathy at prior to enrollment.~* Patients treated with medications that increase the risk of neuropathy like amiodarone, Colchicine, metronidazole, phenytoin.~* Patients with a history of hypersensitivity to metformin.~* Pregnant or lactating females.~* Patients who are using metformin for any other cause.~* Patients with Diabetes mellitus.~* Receiving vitamin B1, B6, B12 or another vitamin supplemental therapy.~* Receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group I (metformin group) (Type: EXPERIMENTAL): who will receive adjuvant paclitaxel in addition to metformin tablets (1700 mg daily) during the chemotherapy treatment duration.
- Group II (control group) (Type: PLACEBO_COMPARATOR): who will receive adjuvant weekly paclitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior to study specific examinations the patient has to give his/her written informed consent.~* Local allergic rhinitis induced by Dermatophagoides pteronyssinus (DP).~* Age: 18-55.~* Negative skin prick-test to DP~* Positive nasal allergen provocation test to DP (NAPT-DP) and/or nasal specific IgE (sIgE) to DP\>0.35 kU/L~* If applicable negative urine pregnancy test and willingness to use effective form of contraception for the duration of involvement in the study.~Exclusion Criteria:~* Severe immunopathological or immunodeficiencies diseases.~* Treatment with beta-blockers, even when administered topically~* Severe psychological disorders~* Severe Atopic Dermatitis~* FEV1 \<70% predicted after appropriate pharmacological treatment~* History of hypersensitivity or intolerance to excipients and / or trial medication or other medication to be used for protocol~* Inability to adequately perform diagnostic tests or treatment~* Awareness of other inhaled allergens (perennial or seasonal) clinically relevant to the subject and that may interfere with the response evaluation~* Treatment with immunotherapy in the 5 years prior to his inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Pangramin Plus D. pteronyssinus (Type: ACTIVE_COMPARATOR): Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRenatal Video-Based Education and PostPARtum Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women who:~  1. have a pre-pregnancy BMI ≥ 25~ 2. are ≥ 18 years~ 3. are English-speaking~ 4. are 34 0/7-36 6/7 gestational weeks~ 5. are nulliparous~ 6. intend to/have interest in breastfeeding after birth~ 7. are having a singleton pregnancy~ 8. plan to receive prenatal care and deliver at select hospital/birth facility systems (access to EMR data)~Exclusion Criteria:~1. contraindications to breastfeeding as specified by the American Academy of Pediatrics~2. history of breast reduction surgery or radiation~3. indication for delivery by 37 weeks gestation~4. gestational or pre-existing diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Antenatal Milk Expression (AME) Intervention Group (Type: EXPERIMENTAL): Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
- Video-based Infant Care Education Control Group (Type: ACTIVE_COMPARATOR): Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutraceutical in Cardiovascular Primary Prevention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥18 years; Ability to provide informed written consent and to participate in the 16 weeks follow-up period And one of the following criteria~* Cardiovascular risk (SCORE) \<1% and LDL levels ≥ 190 mg/dl (confirmed after a 4-week period of life style changes)~* Cardiovascular risk (SCORE) 1% to \<5% and LDL levels ≥ 100 mg/dl (confirmed after a 4- week period of life style changes)~Exclusion Criteria:~Chronic liver disease Renal disease (creatinine clearance \<60 mg/dl) Intolerance to nutraceutical compounds Thyroid disease Alcohol consumption \>40 g/die Treatment with lipid lowering products in the previous 4 weeks Known coronary artery disease (CAD) or cerebrovascular disease Cardiovascular risk (SCORE) ≥5%

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- nutraceutical (Type: EXPERIMENTAL): after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal for 5 or more years, defined as no menses for at least 5 years OR at least 5 years status post bilateral oophorectomy~* Bone mineral density T-score at the hip or spine of -2.0 or less~* Spinal anatomy suitable for dual-energy x-ray absorptiometry (DXA). At the lumbar spine, there is no evidence of vertebral fracture in at least 3 vertebrae in the L1 to L4 region on baseline spine films. (Significant scoliosis, bony trauma, degenerative joint disease, and sequelae of orthopedic procedures that result in anatomy that is unsuitable for accurate bone densitometry must be absent from the lumbar spine.)~* At least one hip must be evaluable by DXA (e.g., contain no hardware from orthopedic procedures)~* In a state of general health allowing for successful completion of the trial~* Agreement to not use any medications to treat osteoporosis during the study~Exclusion Criteria:~* History of prior osteoporotic fracture (unless declined treatment with or was ineligible for osteoporosis therapy)~* Past treatment with osteoporosis medications, steroids, hormone replacement, as well as various other medications that affect bone may be exclusionary. (Different exclusion criteria apply to each bone active drug. For example, any prior use of intravenous (IV) bisphosphonates is not permitted. By contrast, prior use of hormone replacement for several years is permitted if it has not occurred within the past 6 months. Please ask the study doctor for details)~* Significant clinical or laboratory abnormalities at the screening visit for the study that, in the opinion of the investigator, could complicate interpretation of the study results or pose additional risk to the patient (for example, patients who are non-ambulatory should be excluded for this reason)

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Odanacatib 3 mg (Type: EXPERIMENTAL): None
- Odanacatib 10 mg (Type: EXPERIMENTAL): None
- Odanacatib 25 mg (Type: EXPERIMENTAL): None
- Odanacatib 50 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Leptin Replacement in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children with a functional leptin gene mutation from a consanguineous Turkish family. Only one leptin-naïve child from this family is alive and eligible.~Exclusion Criteria:~* N/A

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant Methionyl Human Leptin (Type: EXPERIMENTAL): Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete